Loading
BNT324 is an experimental antibody-drug conjugate from BioNTech SE in phase 3 trials for prostate cancer and non-small-cell lung cancer, aimed at B7-H3.
BNT324 (DB-1311) is an antibody-drug conjugate developed by BioNTech SE. Its target is B7-H3 (the sponsor names B7-H3). The sponsor states: BNT324 (DB-1311) is an antibody-drug conjugate targeting B7-H3, given as an intravenous infusion in 21-day cycles; a phase 3 trial compares it with docetaxel in metastatic castration-resistant prostate cancer. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07365995 (A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer), in prostate cancer and non-small-cell lung cancer. The largest, NCT07365995, plans to enrol 736 participants with primary completion expected 2031-02. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
BNT324 (DB-1311) is an antibody-drug conjugate targeting B7-H3, given as an intravenous infusion in 21-day cycles; a phase 3 trial compares it with docetaxel in metastatic castration-resistant prostate cancer. Connects to B7-H3.
1.BNT324's antibody arm binds B7-H3 on the surface of the cancer cell.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"BNT324" OR ABSTRACT:"BNT324" OR TITLE:"DB-1311" OR ABSTRACT:"DB-1311") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BNT324, not a curated reading list.
Shares BioNTech and the tag pipeline.
Shares BioNTech and the tag pipeline.
Shares BioNTech and the tag pipeline.
Shares B7-H3 and the tag pipeline.
Shares Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares B7-H3, Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares BioNTech and the tag pipeline.
Shares BioNTech and the tag pipeline.